Discover our main news for the first half of 2022!
Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
|
|
Explicyte’s partnership with Domain Therapeutics has been running since this year!
Explicyte is very proud to have granted Domain Therapeutics the exclusivity on data related to GPCR implicated in immunoresistance, in order to develop innovative, first-in class cancer therapies.
|
|
 |
|
|
|
|
|
|
|
  |
|
New cutting-edge platforms for biomarker translational research
Thanks to its certified partnerships, Explicyte now offers:
- Spatial transcriptomics to deal with the tumor biology complexity & heterogeneity
- High proteomic analysis capabilities for comprehensive protein biomarker discovery
|
|
|
Discover our newest featured publications
Led in collaborations with renowned researchers, many of our works underlining Explicyte’s expertise and strengths were recently published in peer-reviewed journals.
|
|
 |
|
